Receive The Newest Study Notifications

Gamma-sarcoglycanopathy (LGMD2C) is one of the most common limb-girdle myopathies. It affects less than 10 people per 1,000,000 and is characterized by progressive muscle weakness in the pelvis (pelvic girdle) and shoulders (scapular girdle), linked to mutations in...

Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced the results of the Phase II study of tradipitant in gastroparesis were presented at Digestive Disease Week® (DDW) 2019 in San Diego, CA. For more information on DDW 2019, please refer...

MDG1021 selected as Medigene's next proprietary clinical TCR-T candidate Preparations ongoing for a Phase I clinical trial in relapse after allogeneic hematopoietic stem cell transplantation Clinical trial start scheduled for 2020 Medigene AG (FSE: MDG1, Prime...

Enrollment in AzurRx’s Phase II OPTION study has reached target of 30-35 patients Screening activities have been completed in AzurRx’s Phase II Option study Top-line data expected in Summer 2019 NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc....

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA ® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary endpoint. Treatment...

- BIO89-100 was generally safe and well tolerated at all dose levels - - Robust and durable pharmacodynamic effects observed across key lipid parameters - 89bio LTD, a clinical-stage biopharmaceutical company focused on nonalcoholic steatohepatitis (NASH) and other...

The "The New Clinical Trial Regulation: Overview and Impact" conference has been added to ResearchAndMarkets.com's offering. This course will provide an essential understanding to help with compliance with the new regulation and associated implementing acts and other...

TrialScout™, a powerful and dynamic platform developed by Circuit Clinical™ that aims to help patients find, choose, and rate their clinical trial experiences, has transformed the clinicaltrials.gov national trial database into a patient-friendly interface, revealing...

When advertising for clinical trials, you want to think of fresh and unique ways to capture potential patient's attention and persuade them to get involved, all while adhering to federal guidelines. While this may sound like a complex advertising campaign, keeping the...

First-of-its-kind study seeking to evaluate the potential anti-tumor effect of the IL-12, IDO1 and anti-PD-1 triple combination OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a late-stage cancer biotechnology company developing intratumoral gene-delivery...

Ascentage Pharma, a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, hepatitis B virus and age-related diseases, today announced the presentation of new clinical data for its investigational apoptosis-targeted...

The "Targeting the CD47-SIRPA Axis in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com'soffering. Targeting the CD47-SIRPa axis is emerging as one of the most promising new cancer immunotherapy approaches seeking to target innate immune...

NeoImmuneTech, Inc. (NIT), a T cell-focused immunotherapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has allowed the Center for Cancer Research, National Cancer Institute to proceed with an Investigational New Drug application (IND)...

MediPharm Labs enters major U.S. led opioid clinical research trial to develop IP and exclusively manufacture CBD gelcaps MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs”) a leader in specialized, research-driven cannabis extraction and...

Nordic Nanovector ASA (OSE: NANO) announces that following a safety review of the first patients in the ongoing Archer-1 (LYMRIT 37-07) trial investigating Betalutin® (177Lu-satetraxetan-lilotomab) in combination with rituximab (RTX) in second-line follicular lymphoma...

- Humanity & Health Research Centre conducting differentiated Phase 2a study evaluating CC-31244 for the ultra-short treatment of hepatitis C (HepC) - Asia market represents one of the largest HepC virus carrier populations in the world BOTHELL, WA, May 20, 2019...

SpringWorks Therapeutics, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in the Phase 3 “DeFi” (Desmoid/Fibromatosis)...

Invivoscribe, Inc., a vertically integrated global company focused on Improving Lives with Precision Diagnostics®, today announces expansion of space and testing capabilities in their international network of accredited LabPMM® clinical laboratories. Additions to the...

Crinetics Pharmaceuticals, Inc. (CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the initiation of a Phase 1,...

A clinical trial, coordinated by researchers from Queen Mary University of London, is currently recruiting patients in London to see whether a new cholesterol-lowering drug could save lives in people who are intolerant to statins. Cardiovascular disease is the number...